---
document_datetime: 2024-02-21 17:19:41
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trecondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trecondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5278599
conversion_datetime: 2025-12-23 08:15:05.154058
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Trecondi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                      |
|----------------------|---------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10777 /202306  | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product) | 11/01/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                            |
| R/0019               | Renewal of the marketing authorisation.                                                     | 09/11/2023                          | 05/01/2024                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Trecondi in the approved indication remains favourable and |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------|
| II/0014 | Extension of indication to include additional non- malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC- FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non- malignant diseases. Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted. | 26/01/2023 | 06/03/2023 | SmPC and PL | Please refer to Scientific Discussion Trecondi-H-C- 004751/II/0014                          |

<div style=\"page-break-after: always\"></div>

|                     | Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                               |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10777 /202206 | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/01/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                             |
| II/0016             | Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced- intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 10/11/2022 | 06/03/2023 | SmPC and PL | Please refer to Scientific Discussion 'Trecondi-H-C-004751- II-0016' For more information, please refer to the Summary of Product Characteristics.                                            |
| II/0012             | Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.1 of the RMP has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                       | 27/10/2022 | 06/03/2023 | SmPC        | Not applicable Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-Var.No' SmPC new text For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| II/0013   | Update of section 5.3 of the SmPC in order to update the description of non-clinical information regarding musculoskeletal and connective tissue disorders in form of lympho-histiocytic infiltration in the skeletal muscles and renal and urinary disorders which show up as haematuria. These new determinations are based on results from study LPT 37259. A revised RMP version 1.2 was submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 29/09/2022   | 06/03/2023   | SmPC   | data                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|------------------------|
| IB/0017/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor test procedure                                                                                                                                                                                 | 10/06/2022   | n/a          |        | changes to an approved |
| IA/0015   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/04/2022   | n/a          |        |                        |
| IA/0011/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                       | 08/02/2022   | n/a          |        |                        |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                        |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10777 /202106 | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product)                                                                                                                                                                                                               | 13/01/2022 | n/a | PRAC Recommendation - maintenance |
| IB/0010             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                | 03/12/2021 | n/a |                                   |
| PSUSA/10777 /202012 | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product)                                                                                                                                                                                                               | 08/07/2021 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10777 /202006 | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product)                                                                                                                                                                                                               | 14/01/2021 | n/a | PRAC Recommendation - maintenance |
| IB/0006             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                    | 21/12/2020 | n/a |                                   |
| II/0004/G           | This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting | 24/09/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |            |                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| II/0003/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.1.c - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/07/2020 | 10/11/2020 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

| new specification parameter its corresponding test method B.II.d.1.c - Change in and/or limits of the finished new specification parameter its corresponding test method B.II.d.1.c - Change in and/or limits of the finished new specification parameter its corresponding test method B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.e - Change in and/or limits of the finished outside the approved specifications B.II.d.1.z - Change in and/or limits of the finished B.II.d.2.a - Change in product - Minor changes procedure B.II.d.2.a - Change in product - Minor changes procedure B.II.d.2.a - Change in   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)   |            |            |                       |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| PSUSA/10777 /201912 | Periodic Safety Update EU Single assessment - treosulfan (for centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/07/2020 | n/a        |                       | PRAC Recommendation - maintenance |
| IB/0001             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/03/2020 | 01/04/2020 | SmPC, Annex II and PL |                                   |